In MDS patients, an anti-CD33 monoclonal antibody can reduce MDSC levels, thus blocking the downstream signal transduction of CD33 and preventing the secretion of immunosuppressive cytokines, thereby reducing ROS levels and DNA damage. Here, CD33 is linked to myelodysplastic syndrome.